Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-0021 Therapeutic Window

In-Vivo Score: 0.850 Price: $0.50 Alzheimer disease 3xTg-AD mice with stratified p-tau217 status, IV exosome dosing Status: proposed

What This Experiment Tests

In-Vivo experiment designed to assess clinical efficacy targeting N/A in 3xTg-AD mice with stratified p-tau217 status, IV exosome dosing. Primary outcome: Plasma p-tau217 biomarker levels and amyloid/tau pathology burden

Description

Determine the optimal dosing window for p-tau217-triggered hUC-MSC exosome administration delivering lncRNA-0021, based on biomarker stratification, and evaluate neuroprotective efficacy in 3xTg-AD mice.

TARGET GENE

N/A

MODEL SYSTEM

3xTg-AD mice with stratified p-tau217 status, IV exosome dosing

ESTIMATED COST

$44,000

TIMELINE

11 months

PATHWAY

N/A

SOURCE

auto-generated

PRIMARY OUTCOME

Plasma p-tau217 biomarker levels and amyloid/tau pathology burden

Scoring Dimensions

Protocol

in-vivo

Expected Outcomes

P-tau217-stratified dosing reduces amyloid and tau pathology by >30% and improves cognitive performance (Y-maze, Barnes maze) vs. standard-dose exosome or vehicle controls.

Success Criteria

p-Tau217 plasma levels (ULSA), amyloid/tau IHC burden, cognitive behavioral scores; threshold: p < 0.05 vs. vehicle.

Related Hypotheses (0)

No related hypotheses

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.